NCT04113486 (ENRC) is a clinical trial of Blood test in Carcinoma, Renal Cell, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.

Who is sponsoring NCT04113486?

NCT04113486 is sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT04113486?

Interventions in NCT04113486: Blood test.

What condition does NCT04113486 study?

NCT04113486 studies Carcinoma, Renal Cell.

Is NCT04113486 still recruiting?

NCT04113486 is currently status unknown. Last updated 24 November 2020.

Last reviewed 2020-11-24 · How we verify

NCT04113486: ENRC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations

Status unknown Last updated 24 November 2020

What this trial tests

trial testing Blood test in Carcinoma, Renal Cell in 400 participants. Status unknown.

Timeline

1 October 2019

Primary endpoint
30 June 2022

30 June 2022

Quick facts

Lead sponsor	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	400
Start date	1 October 2019
Primary completion	30 June 2022
Estimated completion	30 June 2022
Sites	1 location across China

Drugs / interventions tested

Blood test — full drug profile →

Conditions studied

Carcinoma, Renal Cell — all drugs for Carcinoma, Renal Cell →

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

18 and older, any sex, with Carcinoma, Renal Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot the ROC curve and establish appropriate cut-off values.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application.
Li M, Li L, Zheng J, Li Z, et al · · 2023 · cited 57× · PMID 36810071 · DOI 10.1186/s12943-023-01745-7

Verify or expand the search:

Other trials of Blood test

Trials testing the same drug.

NCT06863974 — High-throughput Omic Technology for Identification of Biomarkers of Relapsing Acute Disseminated Encephalomyelitis in Im · NA · recruiting
NCT07078435 — Innate Immunity, MIcrobiota and Inovative Treatments in Endometriosis · NA · not yet recruiting
NCT05370300 — SNAPS Breast Cancer Patient Study Breast Cancer Patients · not yet recruiting
NCT06820450 — Pilot Study to Characterize the Endometriosis Steroidome and Its Link to Endocrine Disruptors and Vaginal Dysbiosis · not yet recruiting
NCT06999785 — Assessment of the Impact of Increased Production of Reactive Oxygen Species Produced During Repeated Sessions of Hyperba · NA · recruiting

Other recruiting trials for Carcinoma, Renal Cell

Currently open trials in the same condition.

NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
NCT06222593 — Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant · Phase 1, PHASE2 · recruiting
NCT07166445 — Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT · recruiting
NCT06676527 — Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma · recruiting

Other Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07506811 — Effects of Different Music Tempos on Feeding Outcomes in Preterm Infants · NA · not yet recruiting
NCT07441187 — Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type · not yet recruiting
NCT07375602 — A Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in Children · recruiting
NCT07405658 — Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Ear · not yet recruiting
NCT07381400 — Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Stu · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04113486 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Last refreshed: 24 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04113486.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing